CDH1 and breast carcinoma: Interestingly, the knockdown of ERK5 in the breast cancer cell line MDA-MB-231 and other in vitro cancer cell models leads to a upregulation in CDH1, a decrease of the mesenchymal marker SERPINE1 (the plasminogen activator inhibitor), and an associated decrease in cell migration and invasion [173].